Test of Time Points to Durability of Efalizumab Efficacy and Safety

September 1, 2003

Chicago - The Biologics License Application for efalizumab (Raptiva) for the treatment of moderate-to-severe plaque psoriasis is set to undergo review by the FDA Dermatologic and Ophthalmic Drugs Advisory Committee this month.

Related Content:

News